Log in

NASDAQ:SBPH - Spring Bank Pharmaceuticals Stock Price, Forecast & News

$1.28
-0.05 (-3.76 %)
(As of 02/27/2020 03:17 AM ET)
Today's Range
$1.21
Now: $1.28
$1.39
50-Day Range
$1.11
MA: $1.41
$2.04
52-Week Range
$1.10
Now: $1.28
$11.00
Volume386,087 shs
Average Volume291,302 shs
Market Capitalization$21.14 million
P/E RatioN/A
Dividend YieldN/A
Beta0.53
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV). The company is also developing STimulator of INterferon Genes agonist product candidate, including SB 11285, an immunotherapeutic agent for the potential treatment of selected cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SBPH
CUSIPN/A
Phone508-473-5993

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.15 per share

Profitability

Net Income$-24,100,000.00

Miscellaneous

Employees29
Market Cap$21.14 million
Next Earnings Date5/4/2020 (Estimated)
OptionableNot Optionable

Receive SBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for SBPH and its competitors with MarketBeat's FREE daily newsletter.


Spring Bank Pharmaceuticals (NASDAQ:SBPH) Frequently Asked Questions

What is Spring Bank Pharmaceuticals' stock symbol?

Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH."

How were Spring Bank Pharmaceuticals' earnings last quarter?

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) posted its quarterly earnings results on Friday, February, 14th. The company reported ($0.45) EPS for the quarter, topping the Zacks' consensus estimate of ($0.48) by $0.03. View Spring Bank Pharmaceuticals' Earnings History.

When is Spring Bank Pharmaceuticals' next earnings date?

Spring Bank Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Spring Bank Pharmaceuticals.

What price target have analysts set for SBPH?

6 Wall Street analysts have issued 12-month price targets for Spring Bank Pharmaceuticals' shares. Their forecasts range from $1.50 to $29.00. On average, they anticipate Spring Bank Pharmaceuticals' stock price to reach $11.84 in the next year. This suggests a possible upside of 825.0% from the stock's current price. View Analyst Price Targets for Spring Bank Pharmaceuticals.

What is the consensus analysts' recommendation for Spring Bank Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spring Bank Pharmaceuticals in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spring Bank Pharmaceuticals.

Has Spring Bank Pharmaceuticals been receiving favorable news coverage?

News articles about SBPH stock have trended extremely negative on Thursday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Spring Bank Pharmaceuticals earned a news impact score of -4.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Spring Bank Pharmaceuticals.

Are investors shorting Spring Bank Pharmaceuticals?

Spring Bank Pharmaceuticals saw a increase in short interest in February. As of February 14th, there was short interest totalling 65,300 shares, an increase of 121.4% from the January 30th total of 29,500 shares. Based on an average daily trading volume, of 330,400 shares, the short-interest ratio is currently 0.2 days. Approximately 0.5% of the company's shares are short sold. View Spring Bank Pharmaceuticals' Current Options Chain.

Who are some of Spring Bank Pharmaceuticals' key competitors?

What other stocks do shareholders of Spring Bank Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spring Bank Pharmaceuticals investors own include Intelsat (I), Fossil Group (FOSL), AMC Entertainment (AMC), Bank of America (BAC), Associated British Foods (ABF), Chaarat Gold (CGH), Apollo Global Management (APO), Strongbridge Biopharma (SBBP), China Unicom (Hong Kong) (CHU) and Ciena (CIEN).

Who are Spring Bank Pharmaceuticals' key executives?

Spring Bank Pharmaceuticals' management team includes the folowing people:
  • Mr. Martin J. Driscoll, Pres, CEO & Director (Age 60)
  • Dr. Radhakrishna P. Iyer, Co-Founder, Chief Scientific Officer & Director (Age 69)
  • Dr. Nezam H. Afdhal, Chief Medical Officer (Age 62)
  • Mr. Jonathan P. Freve CPA, CFO & Treasurer (Age 41)
  • Mr. Donald Mitchell MBA, VP of Operations & Corp. Devel.

When did Spring Bank Pharmaceuticals IPO?

(SBPH) raised $14 million in an IPO on Friday, May 6th 2016. The company issued 1,100,000 shares at $12.00-$14.00 per share. Dawson James Securities acted as the underwriter for the IPO.

Who are Spring Bank Pharmaceuticals' major shareholders?

Spring Bank Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BVF Inc. IL (5.78%), Tiedemann Advisors LLC (2.58%), Renaissance Technologies LLC (1.22%), Hikari Power Ltd (0.80%) and Parsons Capital Management Inc. RI (0.56%). Company insiders that own Spring Bank Pharmaceuticals stock include Jonathan Freve, Martin J Driscoll and Scott Andrew Smith. View Institutional Ownership Trends for Spring Bank Pharmaceuticals.

Which institutional investors are selling Spring Bank Pharmaceuticals stock?

SBPH stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Parsons Capital Management Inc. RI, Hikari Power Ltd and Tiedemann Advisors LLC. View Insider Buying and Selling for Spring Bank Pharmaceuticals.

Which institutional investors are buying Spring Bank Pharmaceuticals stock?

SBPH stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Spring Bank Pharmaceuticals stock in the last two years include Jonathan Freve, Martin J Driscoll and Scott Andrew Smith. View Insider Buying and Selling for Spring Bank Pharmaceuticals.

How do I buy shares of Spring Bank Pharmaceuticals?

Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Spring Bank Pharmaceuticals' stock price today?

One share of SBPH stock can currently be purchased for approximately $1.28.

How big of a company is Spring Bank Pharmaceuticals?

Spring Bank Pharmaceuticals has a market capitalization of $21.14 million. The company earns $-24,100,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Spring Bank Pharmaceuticals employs 29 workers across the globe.View Additional Information About Spring Bank Pharmaceuticals.

What is Spring Bank Pharmaceuticals' official website?

The official website for Spring Bank Pharmaceuticals is http://www.springbankpharm.com/.

How can I contact Spring Bank Pharmaceuticals?

Spring Bank Pharmaceuticals' mailing address is 35 PARKWOOD DRIVE SUITE 210, HOPKINTON MA, 01748. The company can be reached via phone at 508-473-5993 or via email at [email protected]


MarketBeat Community Rating for Spring Bank Pharmaceuticals (NASDAQ SBPH)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  214 (Vote Outperform)
Underperform Votes:  255 (Vote Underperform)
Total Votes:  469
MarketBeat's community ratings are surveys of what our community members think about Spring Bank Pharmaceuticals and other stocks. Vote "Outperform" if you believe SBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Featured Article: Pattern Day Trader

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel